Lower riskDrug recall · FDA · Published December 8, 2021
Teva Brinzolamide Ophthalmic Suspension 1% Recall: Cap Notch May Block Dropper
Teva Pharmaceuticals recalls Brinzolamide Ophthalmic Suspension 1% dropper bottles due to a cap notch that may break off and block the dropper, preventing product dispensing.
Defective Container: The notch in the cap that fits into the nozzle of the dropper could break off and block the dropper possibly resulting in the product not dispensing.
Teva Pharmaceuticals is recalling Brinzolamide Ophthalmic Suspension 1% dropper bottles because the cap's notch could break off and block the dropper, potentially preventing the medication from dispensing. This could lead to incomplete treatment if the medication isn't properly administered. Read more at govinfonow.com/recall/35424-teva-brinzolamide-ophthalmic-suspension-1-recall-cap-notch-may-block.
“Teva Brinzolamide Ophthalmic Suspension 1% Recall: Cap Notch May Block Dropper.” GovInfoNow, updated August 18, 2026. https://govinfonow.com/recall/35424-teva-brinzolamide-ophthalmic-suspension-1-recall-cap-notch-may-block. Based on FDA recall #D-0373-2022 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0373-2022%22&limit=1).
The FDA announced on Dec. 8, 2021, that Teva Pharmaceuticals USA is recalling Brinzolamide Ophthalmic Suspension, USP 1%, due to defective containers that may block the dropper. The recall affects specific lots of 10 ml and 15 ml bottles distributed nationwide.
According to the FDA, the notch in the cap that fits into the nozzle of the dropper could break off and block the dropper, possibly resulting in the product not dispensing.
Context
GovInfoNow's records show Teva Pharmaceuticals USA has 97 other recalls on record since Oct. 11, 2013. Other recent recalls of similar products include Teva Doxylamine Succinate Tablets Recall (Jan. 18, 2022), Teva Tretinoin Capsules 10mg Recall (Jan. 10, 2022), and Teva Mimvey Tablets Recall (Jan. 7, 2022). Other recent recalls of similar products include Micro Labs Dorzolamide/Timolol Eye Drops Recall (July 22, 2026) and Teva Clonidine Transdermal System Recall (March 19, 2026).
How to tell if you have this one
Check for Brinzolamide Ophthalmic Suspension 1% dropper bottles with NDC 0591-2127-79 (10 ml) or NDC 0591-2127-12 (15 ml). The product was manufactured in India by Indoco Remedies Limited and distributed by Teva Pharmaceuticals USA.
Brand
Teva Pharmaceuticals
Category
Drug
Based on the official FDA remedy
What to do — step by step
Check Product Details
Look for NDC codes 0591-2127-79 (10 ml) or 0591-2127-12 (15 ml) on the bottle.
Where it went and when
Where it was distributed
Distributed nationwide.
Nationwide
Not listed
FDA distribution: “Nationwide in the USA” States read from FDA’s own wording; “not listed” means the notice does not name it.
Distributed nationwide.
Recall timeline
FDA terminated this recall 18 months after the firm started it.
1Firm started the recall
2FDA classified it Class II
3Published in FDA’s Enforcement Report
4FDA terminated the recall
Dates from the agency record only; steps without a date are left out.
The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.
Official source: FDA Recall #D-0373-2022 (December 8, 2021) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-0373-2022 to see it in context.
Plain-language summary written by qwen3:4b on August 18, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.